✦ LIBER ✦

518 The increased and prolonged epidermal growth factor receptor (EGFR) activation and the effect of EGFR inhibition on cellular proliferation in a human cholangiocarcinoma cell line

✍ Scribed by Jung-Hwan Yoon; Geum-Youn Gwak; Kyung-Suk Suh; Hyo-Suk Lee; Steven F. Bronk; Nathan W. Werneburg; Gregory J. Gores

Book ID: 119530424
Publisher: John Wiley and Sons
Year: 2003
Tongue: English
Weight: 141 KB
Volume: 38
Category: Article
ISSN: 0270-9139
DOI: 10.1016/s0270-9139(03)80560-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The effects of type beta transforming gr

The effects of type beta transforming growth factor on proliferation and epidermal growth factor receptor expression in a human glioblastoma cell line

✍ Eirik Helseth; Geirmund Unsgaard; Are Dalen; Randi Vik 📂 Article 📅 1988 🏛 Springer US 🌐 English ⚖ 582 KB

Type beta transforming growth factor (B-TGF) is a potent growth inhibitor to many human tumor cell lines. Very little is known about the mechanism for this growth inhibitory action of B-TGF. We here report the effect of B-TGF on proliferation and epidermal growth factor receptor (R-EGF) expression i

Inhibition of proliferation and inductio

Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (‘Iressa’) is independent of EGFR expression level

✍ Manuela Campiglio; Alberta Locatelli; Clelia Olgiati; Nicola Normanno; Giulia So 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 297 KB 👁 2 views

High expression of the epidermal growth factor receptor (EGFR) in breast carcinoma confers a growth advantage to the tumor cells. The EGFR tyrosine kinase inhibitor (EGFR-TKI) ZD1839 ('Iressa') has clinical activity in a wide range of tumor types, although the mechanism(s) by which it exerts its ant

Antitumor activity of the selective epid

Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa® (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo

✍ Ichiro Naruse; Tohru Ohmori; Yoko Ao; Hisao Fukumoto; Toshio Kuroki; Masatomo Mo 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 216 KB 👁 1 views

## Abstract Selective tyrosine kinase inhibitors are regarded as promising antitumor agents for cancer treatment. Iressa® (ZD1839) is an orally active, selective EGFR‐TKI (epidermal growth factor receptor‐tyrosine kinase inhibitor) that blocks signal transduction pathways implicated in cancer cell

38: Identification of a Novel Epidermal

38: Identification of a Novel Epidermal Growth Factor Receptor (EGFR) Binding Activity of Cyclin D1 Promoter During HepG2 Cell Proliferation and in Human Hepatocellular Carcinoma

✍ A. Hernandez-Garcia; S. Thevananther; S.S. Awad 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 474 KB

Inhibition of growth and induction of en

Inhibition of growth and induction of enzyme activities in a clonal human hepatoma cell line (Li-7A): Comparison of the effects of epidermal growth factor and an anti-epidermal growth factor receptor antibody

✍ Aileen F. Knowles 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 780 KB

A cloned human hepatoma cell line (Li-7A), possessing epidermal growth factor (EGF) receptors numbering in the range of 10-20 pmol/106 cells, was inhibited in its growth by EGF as well as an antagonist monoclonal antibody (MoAb) to the EGF receptor. The mode of action of the two ligands of EGF recep

Response to dual blockade of epidermal g

Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor

✍ Shirish M. Gadgeel; Shadan Ali; Philip A. Philip; Fakhara Ahmed; Antoinette Wozn 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 332 KB 👁 1 views

## Abstract ## BACKGROUND. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) have demonstrated clinical benefit in patients with nonsmall cell lung cancer (NSCLC), particularly those with tumors that have EGFR‐TK domain mutations. Moreover, the EGFR and cyclooxygenase (COX)‐2